Frequency of Obtaining National Cholesterol Education Program Adult Treatment Panel III Goals for All Major Serum Lipoproteins After Initiation of Lipid Altering Therapy††Conflicts of interest: Drs. Nichols and Brown are employees of Kaiser Permanente Northwest. Drs. Ambegaonkar and Sazonov are employees of Merck & Company, Inc. Drs. Nichols and Brown have received research support from Amgen, Inc., Thousand Oaks, California; Novo Nordisk A/S, Bagsværd, Denmark; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Takeda Pharmaceuticals North America, Inc., Deerfield, Illinois; and GlaxoSmithKline, Inc., London, United Kingdom.

标题

Frequency of Obtaining National Cholesterol Education Program Adult Treatment Panel III Goals for All Major Serum Lipoproteins After Initiation of Lipid Altering Therapy††Conflicts of interest: Drs. Nichols and Brown are employees of Kaiser Permanente Northwest. Drs. Ambegaonkar and Sazonov are employees of Merck & Company, Inc. Drs. Nichols and Brown have received research support from Amgen, Inc., Thousand Oaks, California; Novo Nordisk A/S, Bagsværd, Denmark; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Takeda Pharmaceuticals North America, Inc., Deerfield, Illinois; and GlaxoSmithKline, Inc., London, United Kingdom.

作者

关键词

-

出版物

AMERICAN JOURNAL OF CARDIOLOGY

Volume 104, Issue 12, Pages 1689-1694

出版商

Elsevier BV

发表日期

2009-12-04

DOI

10.1016/j.amjcard.2009.07.050